-
First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing.
Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2014;35:118-26. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
Screening for fetal aneuploidies at 11 to 13 weeks.
Nicolaides KH.
Prenat Diagn 2011;31:7-15. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
Maternal serum alpha-fetoprotein in normal pregnancy at 11-13 weeks' gestation.
Bredaki FE, Wright D, Akolekar R, Cruz G, Nicolaides KH.
Fetal Diagn Ther 2011;30:274-9. -
Maternal serum ADAM12 (A disintegrin and metalloprotease) in chromosomally abnormal pregnancy at 11-13 weeks.
Poon LC, Chelemen T, Minekawa R, Frisova V, Nicolaides KH.
Am J Obstet Gynecol 2009;200:508.1-6. -
Some thoughts on the true value of ultrasound.
Nicolaides KH.
Ultrasound Obstet Gynecol 2007;30:671-4. -
First trimester maternal serum AFP and total hCG in aneuploidies other than trisomy 21.
Spencer K, Heath V, Flack N, Ong C, Nicolaides KH.
Prenat Diagn 2000;20:635-9. -
Fetal hepatic alpha-fetoprotein mRNA expression in fetuses with trisomy 21 and 18 at 12-15 weeks gestation.
Brizot ML, Mckie AT, von-Kaisenberg CS, Farzaneh F, Nicolaides KH.
Early Hum Dev 1996;44:155-9. -
First trimester maternal serum alpha-fetoprotein in fetal trisomies.
Brizot ML, Khun P, Bersinger NA, Snijders RJM, Nicolaides KH.
Br J Obstet Gynaecol 1995;102:31-4.